Free Trial
NASDAQ:MOR

MorphoSys (MOR) Stock Price, News & Analysis

MorphoSys logo
$18.96 0.00 (0.00%)
(As of 12/20/2024 ET)

About MorphoSys Stock (NASDAQ:MOR)

Key Stats

Today's Range
$18.96
$18.96
50-Day Range
$18.96
$18.96
52-Week Range
$4.18
$19.50
Volume
N/A
Average Volume
1.02 million shs
Market Capitalization
$2.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.33
Consensus Rating
Hold

Company Overview

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

MorphoSys Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
2nd Percentile Overall Score

MOR MarketRank™: 

MorphoSys scored higher than 2% of companies evaluated by MarketBeat, and ranked 938th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MorphoSys has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MorphoSys has received no research coverage in the past 90 days.

  • Read more about MorphoSys' stock forecast and price target.
  • Earnings Growth

    Earnings for MorphoSys are expected to grow in the coming year, from ($2.42) to ($1.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MorphoSys is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MorphoSys is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MorphoSys has a P/B Ratio of 54.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for MOR.
  • Dividend Yield

    MorphoSys does not currently pay a dividend.

  • Dividend Growth

    MorphoSys does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MOR.
  • News Sentiment

    MorphoSys has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for MorphoSys this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for MOR on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MorphoSys insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.05% of the stock of MorphoSys is held by insiders.

  • Percentage Held by Institutions

    Only 18.38% of the stock of MorphoSys is held by institutions.

  • Read more about MorphoSys' insider trading history.
Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

MOR Stock News Headlines

Novartis shutters MorphoSys sites, lays off staff
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Novartis raises mid-term sales guidance
See More Headlines

MOR Stock Analysis - Frequently Asked Questions

MorphoSys' stock was trading at $9.90 at the beginning of 2024. Since then, MOR shares have increased by 91.5% and is now trading at $18.96.
View the best growth stocks for 2024 here
.

MorphoSys (MOR) raised $200 million in an initial public offering on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners acted as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

MorphoSys' top institutional investors include Hennion & Walsh Asset Management Inc. (0.08%), GAMMA Investing LLC, Parallax Volatility Advisers L.P. and Centiva Capital LP.

Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), e.l.f. Beauty (ELF), EMCOR Group (EME), Disc Medicine (IRON) and Builders FirstSource (BLDR).

Company Calendar

Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MOR
Employees
730
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.33
High Stock Price Target
$18.25
Low Stock Price Target
$10.40
Potential Upside/Downside
-24.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-205,350,000.00
Net Margins
-226.79%
Pretax Margin
-225.77%

Debt

Sales & Book Value

Annual Sales
$238.28 million
Book Value
$0.35 per share

Miscellaneous

Free Float
150,546,000
Market Cap
$2.86 billion
Optionable
Not Optionable
Beta
1.20
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:MOR) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners